Stability of valacyclovir: Implications for its oral bioavailability

International Journal of Pharmaceutics

Volumn 317, Issue 1, 2006, Pages 14-18

  Granero, Gladys E ^a   Amidon, Gordon L ^b  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Acyclovir; Luminal degradation; Oral availability; Stability; Valacyclovir

Indexed keywords

ACICLOVIR; BUFFER; PHOSPHATE; PRODRUG; VALACICLOVIR;

ACIDITY; ARTICLE; CATALYSIS; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG HALF LIFE; DRUG RELEASE; DRUG STABILITY; HUMAN; INTESTINE FLUID; KINETICS; NONHUMAN; PH; PRIORITY JOURNAL; SHELF LIFE; STOMACH CONTENT;

ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; BUFFERS; DOGS; GASTRIC JUICE; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; INTESTINES; PRODRUGS; VALINE;

EID: 33745007336     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.01.050     Document Type: Article

References (19)

1. Acosta E., and Fletcher C. Valaciclovir. Ann. Pharmacother. 31 (1997) 185-191
2. Balfour H.H., Chace B.A., Stapleton J.T., Simmons R.L., and Fryd D.S. A randomized placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N. Engl. J. Med. 320 (1989) 1381-1387
3. Beauchamp L., Orr G., de Miranda P., et al. Amino acid ester prodrugs of aciclovir. Antivir. Chem. Chemother. 3 (1992) 157-164
4. De Miranda P., and Blum M. Pharmacokinetics of aciclovir after intravenous and oral dosing. J. Antimicrob. Chemother. 12 (1983) 29-37
5. Fletcher C., and Bean B. Evaluation of oral aciclovir therapy. Drug Intell. Clin. Pharm. 19 (1985) 518-524
6. Guo A., Hu P., Balimane P.V., Leibach F.H., and Sinko P.J. Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J. Pharmacol. Exp. Ther. 289 (1999) 448-454
7. Herrera-Ruiz D., Wang Q., Gudmundsson O.S., Cook T.J., Smith R.L., Faria T.N., and Knipp G.T. Spatial expression patterns of peptide transporters in the human and rat gastrointestinal tracts, Caco-2 in vitro cell culture model and multiple human tissues. AAPS Pharm. Sci. 3 (2001) E9
8. Kostenbauder H.B., and Bogardus J.B. Reaction kinetics. In: Gennaro A.R., Chase C.D., Marderosian A.D., Harvey S.C., Hussar D.A., Medwick T., Rippie E.G., Schwartz J.B., Swinyard E.A., and Zink G.L. (Eds). Remington's Pharmaceutical Sciences. 18th ed. (1990), Mack Publishing Company, Easton 247-256
9. Landowski C.P., Sun D., Foster D.R., Menon S.S., Barnett J.L., Welage L.S., Ramachandran C., and Amidon G.L. Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J. Pharmacol. Exp. Ther. 306 (2003) 778-786
10. Lindahl A., Ungell A.-L., Knutson L., and Lennernäs H. Characterization of fluids from the stomach and proximal jejunum in men and women. Pharm. Res. 14 (1997) 497-502
11. Martin A.N. Kinetics. In: Martin A.N., Bustamante P., and Chun A.H.C. (Eds). Physical Pharmacy: Physical Chemical Principles in the Pharmaceutical Sciences. fourth ed. (1993), Lea and Febiger, Philadelphia 284-323
12. Meyers J.D., Reed E.C., Shepp D.H., Thornquist M., Dandliker P.S., Vicary C.A., Flournoy N., Kirk L.E., Kersey J.H., Thomas E.D., and Balfour H.H. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N. Engl. J. Med. 318 (1988) 70-75
13. Nugent S.G., Kumar D., Rampton D.S., and Evans D.F. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 48 (2001) 571-577
14. O'Brien J.J., and Campoli-Richards D.M. Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 37 (1989) 233-309
15. Perry C., and Faulds D. Valaciclovir. Drugs 52 (1996) 754-772
16. Prentice H.G., Gluckman E., Powles R.C., Ljungman P., Milpied N.J.F., Ranada J.M.F., Madelli F., Kho P., Kennedy L., and Bell A.R. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 343 (1994) 749-753
17. Purifoy D., Beauchamp L., de Miranda P., et al. Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride and 882C, a specific agent for varicella. J. Med. Virol. 41 (1993) 139-145
18. Sould-Lawton J., Seaber E., On N., Wootton R., Rolan P., and Posner J. Absolute bioavalilability and metabolic disposition of valaciclovir, the l-valyl ester of acyclovir, following oral administrations to humans. Antimicrob. Agents Chemother. 39 (1995) 2759-2764
19. Weller S., Blum M.R., Doucette M., Burnette T., Cederberg D.M., de Miranda P., and Smiley M.L. Pharmacokinetics of the acyclovir prodrug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin. Pharmacol. Ther. 54 (1993) 595-605